SuperworthANI Pharmaceuticals ANIP
- Market cap
- $1.7B
- PE
- 15.4×
- 10y median 60.6×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 1.7×
- EV/EBIT
- 10.5×
- Revenue, 12 months
- $978.4M
- +31% on a year ago
- Net margin
- 11.1%
- Free cash flow yield
- 10.4%
ANI Pharmaceuticals trades at 15.4× trailing earnings, cheaper than 98% of the last ten years. Revenue was $978.4M over the last twelve months, up 31% on a year earlier with a 11% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $131.8M+57% | $131.7M+40% | $137.4M+29% | $138M+18% | $148.3M+13% | $190.6M+45% | $197.1M+43% | $211.4M+53% | $227.8M+54% | $247.1M+30% | $237.5M+21% | $266M+26% | |
| Cost of revenue | $48.1M+46% | $53.4M+47% | $49.2M+30% | $57.7M+37% | $63.1M+31% | $80.3M+50% | $73M+49% | $74.6M+29% | $93.4M+48% | $100.3M+25% | $93.6M+28% | $100.2M+34% |
| Gross profit | $83.7M+64% | $78.2M+35% | $88.3M+28% | $80.3M+8% | $85.3M+2% | $110.3M+41% | $124.1M+41% | $136.8M+70% | $134.4M+58% | $146.8M+33% | $143.9M+16% | $165.9M+21% |
| R&D | $11.1M+45% | $9.9M+89% | $10.5M+77% | $7.3M−1% | $10.1M−9% | $16.6M+69% | $10.6M+1% | $16.5M+127% | $12.3M+22% | $12.3M−26% | $10.6M+0% | $14.7M−11% |
| SG&A | $42M+40% | $44.5M+34% | $48M+32% | $52.8M+36% | $79.1M+88% | $69.7M+57% | $76.5M+59% | $81.8M+55% | $76.7M−3% | $82.8M+19% | $73.7M−4% | $91.7M+12% |
| $17.9M | $6.7M+270% | $20.3M+105% | $5.2M−58% | −$20.5M | −$4.4M | $26.2M+29% | $13.9M+169% | $36.2M | $34.8M | $38.9M+49% | $40.5M+191% | |
| Interest expense | $6.4M−14% | $14.4M+87% | $9.1M+15% | $9.1M+14% | $6.7M+4% | $8.8M−39% | $8.1M−11% | $8.2M−9% | $8.3M+24% | $8M−10% | $7.6M−7% | $7.5M−9% |
| Pre-tax income | $11.5M | $947K | $25.3M+1070% | −$2.3M | −$31.5M | −$13.8M | $20M−21% | $10.5M | $33.8M | $31.5M | $40.2M+101% | $37.1M+253% |
| $1.6M | −$208K−86% | $7.1M+882% | $0 | −$7.3M | −$3.5M+1576% | $4.3M−40% | $2M | $7.2M | $4M | $10.7M+149% | $12.4M+527% | |
| Net income | $9.9M | $1.2M | $18.2M+1165% | −$2.3M | −$24.2M | −$10.3M | $15.7M−14% | $8.5M | $26.6M | $27.5M | $29.5M+88% | $24.7M+189% |
| $0.45 | $0.04 | $0.82+1267% | −$0.14 | −$1.27 | −$0.55 | $0.69−16% | $0.36 | $1.13 | $1.24 | $1.28+86% | $1.05+192% | |
| 19.1M+17% | 19.3M+18% | 19.4M+18% | 19.3M+8% | 19.4M+2% | 19.4M+1% | 20M+3% | 20.3M+5% | 21.1M+9% | 22.2M+14% | 21.5M+8% | 21.9M+8% |
Gross profit: 57 periods, Q2 FY12 to Q2 FY26: not printed by the filing, worked out from its own lines.
Operating income: Q3 FY11 and Q4 FY11: not printed by the filing, worked out from its own lines.
Net income: 5 periods, Q4 FY10 to Q4 FY12: not printed by the filing, worked out from its own lines.
EPS, diluted: 14 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q2 FY10 and Q3 FY10: not printed by the filing, worked out from its own lines. 10 periods, Q4 FY10 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 6 periods, Q4 FY13 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest ANI Pharmaceuticals' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ANIPANI Pharmaceuticals | $1.7B | 15.4× | 60.6× | 1.7× | +31% | 11.1% | |
| PAHCPhibro Animal Health | $1.6B | 15.9× | 21.5× | 1.0× | +17% | 6.6% | |
| ANABAnaptysbio | $1.5B | 10.7× | 100.0× | n/m | n/m | n/m | |
| PCRXPacira BioSciences | $1.5B | 104× | 65.6× | 1.9× | +6% | 2.0% | |
| HRMYHarmony Biosciences | $2.1B | 11.7× | 13.8× | 2.2× | +24% | 18.9% | |
| PBHPrestige Consumer Healthcare | $2.3B | 13.4× | 15.3× | 2.0× | −1% | 15.6% | |
| OMEROmeros | $1.2B | 10.9× | 11.7× | n/m | n/m | n/m | |
| AMPHAmphastar Pharmaceuticals | $1.1B | 14.8× | 20.6× | 1.5× | +1% | 10.8% | |
| NRIXNurix Therapeutics | $2.8B | 11.0× | 10.8× | 3.9× | n/m | 42.0% | |
| ABUSArbutus Biopharma | $831M | 5.4× | 5.6× | 4.6× | n/m | 84.2% | |
| OGNOrganon | $3.6B | 17.9× | 5.9× | 0.6× | −2% | 3.4% | |
| Peer median | $1.5B | 12.5× | 14.5× | 2.0× | +3% | 13.2% |
More on ANI Pharmaceuticals
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #1of 92Healthcare stocks cheapest against their own PE history
- #1of 17Large drugmakers cheapest against their own PE history
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .